Type 2 drug semaglutide found to reduce HbA1C levels
The type 2 drug semaglutide reduces HbA1C levels, helps weight loss and results in fewer hypoglycaemic episodes than insulin glargine, according to new research.
The research team carried out the work because they said that the many pharmacological treatment options currently available for people with type 2 diabetes, many do not achieve “optimum glycemic control”.
As part of the study they assessed the efficacy and safety of semaglutide, which is a glucagon-like peptide-1 (GLP-1) analogue in clinical development, and compared it to insulin glargine in patients with type 2 diabetes who were inadequately controlled with metformin.
The randomised, open-label, non-inferiority, parallel-group, multicentre, multinational, phase 3a trial was carried out across 196 sites in 14 countries.
Eligible participants were insulin-naive people with type 2 diabetes, aged 18 years and older, who had insufficient glycaemic control with metformin either alone or in combination with a sulfonylurea.
They were randomly assigned to either subcutaneous once-weekly 0·5 mg or 1·0 mg semaglutide (doses reached after following a fixed dose-escalation regimen) or once-daily insulin glargine (starting dose 10 IU per day, then titrated weekly to a pre-breakfast self-measured plasma glucose target of 4·0–5·5 mmol/L [72–99 mg/dL]) for 30 weeks.
The primary endpoint was change in mean HbA1C from baseline to week 30 and the confirmatory secondary endpoint was the change in mean bodyweight from baseline to week 30.
The findings were published in the Lancet Diabetes and Endocrinology journal.